Ganciclovir - Generic Drug Details

What are the generic drug sources for ganciclovir and what is the scope of patent protection?

Ganciclovir is the generic ingredient in six branded drugs marketed by Roche Palo, Ranbaxy Labs Ltd, Bausch And Lomb, Exela Pharma, Cheplapharm, Am Regent, Custopharm Inc, Fresenius Kabi Usa, Hikma, Onesource Specialty, Ph Health, Pharmascience Inc, and Slate Run Pharma, and is included in fourteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for ganciclovir. Two suppliers are listed for this compound.

Summary for ganciclovir

US Patents:	1
Tradenames:	6
Applicants:	13
NDAs:	14
Drug Master File Entries:	27
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	151
Clinical Trials:	163
Drug Prices:	Drug price trends for ganciclovir
What excipients (inactive ingredients) are in ganciclovir?	ganciclovir excipients list
DailyMed Link:	ganciclovir at DailyMed

See drug prices for ganciclovir

Recent Clinical Trials for ganciclovir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Health Network, Toronto	PHASE4
Peking University People's Hospital	PHASE2
Amivas Inc.	PHASE2

See all ganciclovir clinical trials

Pharmacology for ganciclovir

Drug Class	Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Nucleoside Analog Antiviral
Mechanism of Action	DNA Polymerase Inhibitors

Medical Subject Heading (MeSH) Categories for ganciclovir

Antiviral Agents

Anatomical Therapeutic Chemical (ATC) Classes for ganciclovir

J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AD	Antivirals
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for ganciclovir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994		DISCN	Yes	No
Custopharm Inc	GANCICLOVIR SODIUM	ganciclovir sodium	INJECTABLE;INJECTION	212001-001	Jun 20, 2019		DISCN	No	No
Onesource Specialty	GANCICLOVIR SODIUM	ganciclovir sodium	INJECTABLE;INJECTION	204560-001	Nov 17, 2017		DISCN	No	No

Expired US Patents for ganciclovir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997	4,507,305
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994	4,355,032
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997	4,642,346

EU/EMA Drug Approvals for ganciclovir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH..	Vitrasert Implant	ganciclovir	EMEA/H/C/000120The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use).	Withdrawn	no	no	no	1997-03-18

Market Dynamics and Financial Trajectory for Ganciclovir

Last updated: July 27, 2025

---

Introduction

Ganciclovir, a potent antiviral medication primarily used to treat cytomegalovirus (CMV) infections, plays a critical role in managing conditions pervasive among immunocompromised populations such as transplant recipients and HIV-positive patients. As the landscape of infectious disease management evolves, understanding the market dynamics and financial trajectory of ganciclovir is vital for stakeholders, including pharmaceutical companies, investors, healthcare providers, and policymakers. This report delineates the factors influencing ganciclovir’s market growth, competitive landscape, pricing trends, and future revenue prospects.

---

Pharmacological Profile and Clinical Relevance

Ganciclovir, developed in the 1980s, gained FDA approval in 1989 (Vistide), primarily targeting CMV retinitis and prophylaxis in immunocompromised patients. Its mechanism involves inhibition of viral DNA synthesis, reducing CMV viral load. Despite the availability of oral valganciclovir, a prodrug offering improved bioavailability, intravenous ganciclovir remains essential in severe infections or where oral administration is infeasible.

The drug's significance stems from the increasing prevalence of CMV infections owing to expanding immunosuppressive therapy and transplant procedures. This demand sustains ganciclovir's critical position in the antiviral pharmacopeia.

---

Market Dynamics

1. Rising Incidence of CMV and Immunosuppressive Treatments

The expanding global transplant population, including kidney, heart, and liver recipients, drives demand for CMV management solutions. According to the WHO, global transplant numbers are projected to increase annually, which directly correlates with the need for effective antivirals such as ganciclovir [1]. Additionally, increasing HIV/AIDS prevalence in certain regions sustains CMV infection rates, intensifying the need for potent treatments.

2. Patent Status and Market Competition

Ganciclovir was originally developed by Bristol-Myers Squibb (BMS) and subsequently became off-patent, fostering the emergence of generic manufacturers. The availability of generics significantly lowers prices and broadens accessibility, impacting revenue streams for branded formulations. However, patent expirations also open space for biosimilar development, which could further intensify market competition.

3. Formulation Developments and Administration Routes

While intravenous ganciclovir remains the clinical standard for severe infections, the advent of oral valganciclovir has facilitated outpatient management, reducing hospitalization costs. These formulations are often marketed under different brand names, such as Cytovene (brand of ganciclovir) and Valcyte (valganciclovir), affecting market share dynamics.

4. Regulatory Approvals and New Indications

Ongoing clinical trials exploring ganciclovir's efficacy for additional indications—such as congenital CMV infections—may augment market scope. Regulatory approvals in emerging markets and expanding indications in immunocompromised states could also fuel growth.

5. Patent Expiry and Generic Competition

The key patent for Ganciclovir’s initial formulations expired in the early 2000s, catalyzing a wave of generic entrants. This transition considerably deflated prices, with variations in regional patent practices influencing localized market competition.

---

Financial Trajectory

1. Revenue Trends

Historically, ganciclovir generated steady revenues driven by its essential role in transplant medicine and immunocompromised care. Market analysts estimate the global market for ganciclovir and valganciclovir to be valued at approximately USD 200-300 million annually, with growth driven by increasing disease incidence and expanding indications [2].

The rise of generics has compressed profit margins, yet volume remains high, especially in regions with high transplant rates. In the U.S. and Europe, branded formulations still capture a segment, but generics dominate due to their affordability.

2. Regional Market Variations

Developed markets, such as North America and Europe, exhibit higher per-unit prices and better reimbursement frameworks, leading to more robust revenue streams for branded drugs. Conversely, emerging markets prioritize generics, where price sensitivity constrains pharmaceutical revenues.

3. Impact of Biosimilars and Competitive Landscape

The potential entry of biosimilars or improved formulations may further commoditize ganciclovir. While no biosimilars for ganciclovir are currently approved, ongoing patent cliffs might incentivize product innovation, influencing future market share and revenues.

4. Cost-Management and Pricing Strategies

Pharmaceutical companies are increasingly adopting pharmacoeconomic approaches to justify pricing, particularly in high-cost healthcare systems. Negotiations with payers and formulary placements significantly impact sales performance.

---

Market Challenges and Opportunities

Challenges:

• Generic Competition: Erode profit margins and market control for branded drugs.
• Pricing Pressures: Heightened with healthcare cost containment policies globally.
• Emerging Resistance: Though limited, potential antiviral resistance may necessitate combination therapies or new formulations.
• Regulatory Hurdles: Stringent regulations can delay market entry for new formulations or indications.

Opportunities:

• Expanding Indications: Clinical development for congenital CMV or prophylactic applications.
• Novel Formulations: Liposomal or targeted delivery systems to improve efficacy and compliance.
• Regional Expansion: Untapped markets in Asia-Pacific, Middle East, and Africa.

---

Future Outlook

The future of ganciclovir's market hinges on demographic trends, technological innovations, and regulatory changes. The increasing global transplant rate and the persistent burden of CMV infections anticipate a resilient demand, albeit moderated by generics. Market growth may stabilize or slightly decline in mature regions, but emerging markets offer sizeable growth opportunities.

Investments in drug delivery systems and combination regimens could provide differentiation and extend the product lifecycle. Additionally, the emergence of sustained-release formulations and alternative antiviral drugs for CMV could reshape the competitive landscape, impacting ganciclovir's financial trajectory.

---

Key Takeaways

• Demand Drivers: The expanding transplant population and HIV prevalence sustain the need for ganciclovir, though largely met through generics.
• Pricing Trends: Patent expirations have led to significant price reductions, impacting profit margins for branded formulations.
• Market Competition: High generic penetration offers volume-based revenue but constrains margins; future biosimilars may further intensify competition.
• Growth Opportunities: Clinical expansion into new indications and regional market penetration, especially in emerging economies, can drive revenues.
• Strategic Focus: Innovation in formulation, combination therapies, and targeted delivery remains critical for sustainable growth.

---

FAQs

1. How does patent expiration affect ganciclovir's market?
Patent expiration allows generic manufacturers to produce lower-cost versions, significantly reducing prices and increasing market accessibility. While this benefits healthcare affordability, it diminishes revenue for original patent-holders.

2. What are the key regions driving ganciclovir sales?
North America and Europe remain major markets due to high transplant rates and healthcare expenditures. Emerging markets in Asia-Pacific and Latin America also contribute, driven by increasing healthcare infrastructure.

3. Are there emerging alternatives to ganciclovir?
Yes. Valganciclovir, an oral prodrug, offers convenience, while newer antiviral agents like brincidofovir are under investigation, though none have yet replaced ganciclovir as the primary treatment.

4. What future clinical developments could impact the ganciclovir market?
Potential approvals for prophylactic or congenital CMV indications and innovative formulations could expand its use, sustaining or increasing its market share.

5. How might biosimilars influence ganciclovir's future?
While biosimilars for ganciclovir are not yet available, their entry could further reduce prices and threaten existing branded formulations, shifting market dynamics and profit pools.

---

Sources

[1] World Health Organization. Transplantations Statistics. 2022.
[2] MarketWatch. Ganciclovir Market Report. 2023.